More than just an academic interest...

As hedge funds move down the liquidity curve, they could do worse than look to universities' increasingly aggressive commercialisation of their academics' R&D, and hunt for helping hands...

What do the names PowderJect, Aim-listed Celoxia, Oxford BioMedica and Oxford Instruments have in common?

They have all been spin-outs from leading UK universities. The secondary connection, however, is that such businesses have made their early stage investors - business angels and venture capitalists including hedge funds - some handsome returns.

With more hedge funds getting involved further down the 'liquidity curve,' and even though the initial outlays required by such start-ups may be small

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here